One year follow-up cardiovascular outcomes of Coraxel brand paclitaxel eluting stents: a single center experience

Abstract

Coraxel (Alvimedica) stents are among those that contain paclitaxel and differ from other paclitaxel eluting stents (PES) in the amount of drug they contain. In this context, it is not known whether the clinical effects of Coraxel stents are different or not. In this study, the clinical effects of Coraxel stents were studied. This study was a single-centered, prospective, non-randomized real life study. Patients to whom stents of Coraxel brand were implanted were followed up in 1-, 3-, 6- and 12-month periods between May 2011 and August 2013 for target lesion revascularization (TLR), stent thrombosis and major cardiovascular events. This study enrolled a total of 78 cases. 82.1% of the cases were male. Average age was 61±11 years. Average stent length was 26.91±11.24 mm, and average stent size was 2.73±0.28 mm. 28% of the patients had TLR, 5 (6%) cases had stent thrombosis, 3 (4%) cases death from all causes, 1 (1%) case cardiac death and 55% of the cases showed major cardiovascular events. TLR, major cardiovascular event and stent thrombosis were observed more frequently in the patients using Coraxel PSS compared to those using TAXUS PSS. [Med-Science 2017; 6(2.000): 305-9]

Keywords

• Drug eluting stents
• target lesion revascularization
• stent thrombosis
• major cardiovascular events